Brief: Cantargia Reports Positive Results On Biomarkers, Safety In CAN10 Phase 1 Clinical Study
11/10/2024 11:17
Oct 11 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS NEW POSITIVE RESULTS ON BIOMARKERS AND
SAFETY
IN CAN10 PHASE 1 CLINICAL STUDY
Source text for Eikon: ID:nMFNbrj3S
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML